share_log

RBC Capital Reiterates Outperform on Insmed, Maintains $100 Price Target

Benzinga ·  Mar 19 14:40  · Ratings

RBC Capital analyst Leonid Timashev reiterates Insmed (NASDAQ:INSM) with a Outperform and maintains $100 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 315

Recommended

Write a comment